Summary:
Long-wavelength ultraviolet A (340–400 nm UVA1) phototherapy has been reported to be effective in atopic dermatitis, localized scleroderma and other T-cell-derived skin diseases. UVA1 as an adjunct to systemic immunosuppressive treatment was found to be safe, and effective in 10 patients with chronic cutaneous (seven lichenoid and three sclerodermoid) graft-versus-host disease (GVHD) after stem cell transplantation. Complete and partial responses were achieved in six (60%), and in three (30%) patients, respectively. One patient had improvement of sclerotic skin lesions. At a median follow-up of 14 months, two patients with lichenoid lesions relapsed. Both responded to another treatment cycle. Furthermore, we treated seven patients with UVA1 as primary therapy for acute cutaneous GVHD grades II and III in a pilot experience. Five patients had a complete response with no relapse at a median follow-up of 9 months after UVA1. Two patients showed no response and systemic steroids had to be started. UVA1 therapy is feasible, well tolerated and can be effective in treating chronic as well as acute GVHD confined to the skin thereby avoiding systemic steroids. Our results should be confirmed in larger studies and the effectiveness of UVA1 compared to other established treatment modalities.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Storb R, Deeg HJ, Whitehead J et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft-versus-host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314: 729–735.
Beatty PG, Hanson JA, Longton GM et al. Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies. Transplantation 1991; 51: 443–447.
Ringden O, Backman L, Lonnqvist B et al. A randomized trial comparing use of cyclosporin and methtrexate for prophylaxis of graft-versus-host disease in bone marrow transplant recipients with hematological malignancies. Bone Marrow Transplant 1986; 1: 41–51.
Sullivan K, Agura E, Anasetti C . Chronic graft versus host disease and other late complications of bone marrow transplantation. Semin Hematol 1991; 28: 250–259.
Vogelsang GB, Lee L, Bensen-Kennedy DM . Pathogenesis and treatment of graft-versus-host-disease after bone marrow transplant. Annu Rev Med 2003; 54: 29–52.
Simon JC, Pfleger D, Schopf E . Recent advances in phototherapy. Eur J Dermatol 2000; 10: 642–645.
Dawe RS . Ultraviolet A1 phototherapy. Topical review. Br J Dermatol 2003; 148: 626–637.
Grundmann-Kollmann M, Behrens S, Gruss C et al. Chronic sclerodermic graft-versus-host disease refractory to immunosuppressive treatment responds to UVA1 phototherapy. J Am Acad Dermatol 2000; 42: 134–136.
Staender H, Schiller M, Schwarz T . UVA1 therapy for sclerodermic graft-versus-host disease of the skin. J Am Acad Dermatol 2002; 46: 799–800.
Calzavara Pinton P, Porta F, Izzi T et al. Prospects for ultraviolet A1 phototherapy as a treatment for chronic cutaneous graft-versus-host disease. Haematologica 2003; 88: 1169–1175.
Glucksberg H, Storb R, Fever A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA matched sibling donors. Transplantation 1974; 18: 295–304.
Thomas ED, Storb R, Clift RA et al. Bone marrow transplantation. N Engl J Med 1975; 292: 895–902.
Doney KC, Weiden PL, Storb R et al. Treatment of graft-versus-host disease in human allogeneic marrow graft recipients: a randomized trial comparing antithymocyte globulin and corticosteroids. Am J Hematol 1981; 11: 1–8.
Arai S, Vogelsang GB . Management of graft-versus-host disease. Blood Rev 2000; 14: 190–204.
Aubin F, Brion A, Deconinck E et al. Phototherapy in the treatment of cutaneous graft-versus-host disease. Our preliminary experience in resistant patients. Transplantation 1995; 59: 151–155.
Eppinger T, Ehninger G, Steinert M et al. 8-Methoxypsoralen and ultraviolet A therapy for cutaneous manifestations of graft-versus-host disease. Transplantation 1990; 50: 807–811.
Leiter U, Kaskel P, Kraehn G et al. Psoralen plus ultraviolet-A-bath photochemotherapy as an adjunct treatment modality in cutaneous chronic graft versus host disease. Photodermatol Photoimmunol Photomed 2002; 18: 183–190.
Furlong T, Leisenring W, Storb R et al. Psoralen and ultraviolet A irradiation (PUVA) as therapy for steroid-resistant cutaneous acute graft-versus-host disease. Biol Blood Marrow Transplant 2002; 8: 206–212.
Wiesmann A, Weller A, Lischka G et al. Treatment of acute graft-versus-host disease with PUVA (psoralen and ultraviolet irradiation): results of a pilot study. Bone Marrow Transplant 1999; 23: 151–155.
Reinauer S, Lehmann P, Plewig G et al. Photochemotherapy (PUVA) of acute graft-versus-host disease. Hautarzt 1993; 44: 708–712.
Wetzig T, Al-Ali HK, Kirstner S et al. Primary PUVA phototherapy can be effective for acute graft-versus-host disease of the skin. Bone Marrow Transplant 2004; 33: 183 (Abstract).
Greinix HT, Volc-Platzer B, Kahls P et al. Extracorporeal photochemotherapy in the treatment of severe steroid-refractory acute graft-versus-host disease: a pilot study. Blood 2000; 96: 2426–2431.
Greinix HT, Volc-Platzer B, Rabitsch W et al. Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease. Blood 1998; 92: 3098–3104.
Morita A, Werfel T, Stege H et al. Evidence that singlet oxygen-induced human T helper cell apoptosis is the basic mechanism of ultraviolet-A radiation phototherapy. J Exp Med 1997; 186: 1763–1768.
Grewe M, Gyufko K, Schopf E et al. Lesional expression of interferon-ã in atopic eczema. Lancet 1994; 343: 25–26.
Krutmann J . Ultraviolet A radiation-induced immunomodulation: molecular and photobiological mechanisms. Eur J Dermatol 1998; 8: 200–202.
Petersen MJ, Hansen C, Craig S . Ultraviolet A irradiation stimulates collagenase production in cultured human fibroblasts. J Invest Dermatol 1992; 99: 440–444.
van Kranen HJ, de Laat A, van de Ven J et al. Low incidence of p53 mutations in UVA (365-nm)-induced skin tumors in hairless mice. Cancer Res 1997; 57: 1238–1240.
Wallenfang K, Stadler R . Assoziation zwischen UVA1 bzw. Bade-PUVA-Bestrahlung und Melanomentwicklung? Hautarzt 2001; 52: 705–707.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wetzig, T., Sticherling, M., Simon, JC. et al. Medium dose long-wavelength ultraviolet A (UVA1) phototherapy for the treatment of acute and chronic graft-versus-host disease of the skin. Bone Marrow Transplant 35, 515–519 (2005). https://doi.org/10.1038/sj.bmt.1704804
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1704804
Keywords
This article is cited by
-
Phototherapie sklerosierender Hautkrankheiten
hautnah dermatologie (2017)
-
More than skin deep? Emerging therapies for chronic cutaneous GVHD
Bone Marrow Transplantation (2013)
-
Associations between environmental factors and incidence of cutaneous melanoma. Review
Environmental Health (2012)
-
UVA (UVA-1) therapy for the treatment of acute GVHD of the skin
Bone Marrow Transplantation (2010)